Developer docs
API playgroundTry for free, no card

Search company profiles

EnsiliTech

Full company profile

uuid00004gz

Namestring
EnsiliTech
Legal namestring
Ensilicated Technologies Ltd.
Websiteurl
ensilitech.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

EnsiliTech (legal name: Ensilicated Technologies Ltd.) is a Bristol, UK-based biopharmaceutical company founded in July 2022 as a spin-out from the University of Bath, where co-founder and CEO Dr Asel Sartbaeva spent 12 years developing the underlying technology. The company commercializes Ensilication®, a patent-protected method of encasing thermally unstable biomolecules within an inert silica (glass) network that preserves their integrity across a temperature range of -80°C to +50°C, removing dependence on cold-chain refrigeration and lyophilization. Application areas span therapeutic and diagnostic antibodies, mRNA and other genetic material, subunit/viral/virus-like/bacterial vaccines, anti-microbial resistance products, probiotics, and enzymes for human, animal, and laboratory research use. EnsiliTech is developing lead programs including the world's first thermally stable mRNA vaccine against Hantaan Virus (funded by a ~£1.7M UK Government SBRI contract awarded January 2024) and a Nipah virus vaccine for livestock (two-year £1.5M DHSC/UK Vaccine Network project in consortium with Pirbright Institute, FLI, and partners), alongside a £1.4M Innovate UK–funded monoclonal antibody manufacturing project with CPI based on Trastuzumab.

The company's business model is a B2B technology licensing and co-development platform aimed at pharmaceutical and biotechnology manufacturers, with a stated pipeline of live commercial negotiations with billion-euro pharma partners. The GTM motion is sales-led enterprise licensing supported by co-development and validation partnerships with technology innovation centers (CPI), global health consortia (Afrigen, EmerVax, Pirbright, FLI, Global Access Diagnostics), and government health agencies (UK DHSC, Innovate UK, UK Vaccine Network). To date, ~£5.7M has been raised in equity (£1.2M pre-seed in January 2023 led by Science Angel Syndicate; £4.5M seed in August 2025 led by Eos Advisory) and an additional ~£4.6M in non-dilutive government grants. Revenue is currently grant-driven; commercial licensing royalties are not yet booked. The team comprises approximately 14–19 personnel — scientists, project managers, and executives — led by founder/CEO Dr Sartbaeva with commercial oversight from CCO Dr Simon Bennett (three decades of bio-pharma deals) and Chair Dr Tim Sparey (US$6B+ in life sciences transactions). The company is registered in England and Wales (company number 13537400) and holds granted patents, registered trademarks, and a growing IP portfolio, with the platform recognized through numerous awards including UK StartUp Awards 2025 (Overall StartUp of the Year South West) and the Allica Bank Great British Entrepreneur Awards 2025.

Short descriptiontext

EnsiliTech is a Bristol-based biopharmaceutical spin-out from the University of Bath that licenses its patent-protected Ensilication® silica-encasement technology to pharma and biotech companies, enabling cold-chain-free storage of vaccines, antibodies, mRNA, and other biologics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical stabilization technology, cold-chain-free vaccines, vaccine thermostabilization platform, biomolecule silica encapsulation, biologics preservation technology
Industry3 codes
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAC
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAMAF
Packaging, Insulation & Temperature-Controlled Shippers (Qualified Systems)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code1 code
  • Air-Conditioning and Warm Air Heating Equipment and Commercial and Industrial Refrigeration Equipment Manufacturing333415
SIC code1 code
  • Gaskets, Packg & Sealg Devices & Rubber & Plastics Hose3050
Product category
Biopharmaceutical Stabilization Technology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Plans to license Ensilication technology to biopharma companies to create heat-stable versions of their medicines. The company is in live commercial negotiations with billion-euro pharma partners for technology integration.

ensilitech.com
2Government R&D Contracts
TypeProfessional Services
Description

Awarded UK Government SBRI research contracts (~£1.7M for Hantaan virus vaccine). Innovate UK grant funding for collaborative R&D projects. These represent non-dilutive funding for technology development and validation.

ensilitech.com
3Collaborative R&D / Service Fees
TypeProfessional Services
Description

Collaborative development agreements with pharmaceutical partners such as CPI for antibody manufacturing, and consortium projects with Pirbright, Afrigen, and EmerVax. Revenue may come from development fees, milestone payments, and validation study contracts.

techround.co.uk
Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EnsiliTech develops and licenses Ensilication®, a patent-protected platform technology that encases thermally unstable biomolecules (vaccines, antibodies, enzymes, mRNA, probiotics) within a silica network to prevent degradation at temperatures from -80°C to +50°C, eliminating the need for cold-chain refrigeration. The company licenses this stabilization technology to biopharma manufacturers and conducts collaborative R&D projects with research institutes and government agencies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EnsiliTech offers the Ensilication® platform technology as its core product—a novel, patent-protected method for stabilizing biopharmaceuticals without refrigeration. The platform encases thermally unstable biomolecules (vaccines, antibodies, enzymes, genetic material, probiotics) within a silica network, allowing storage and transport at temperatures from -80°C to +50°C. The company licenses this technology to biopharma companies and is applying it through several programs including development of a thermally stable mRNA vaccine against Hantaan Virus (via SBRI contract) and antibody stabilization (via CPI partnership grant). EnsiliTech also publishes white papers and research to demonstrate the technology's application and economics.

Product and service1 record
1Ensilication® Platform Technology
CategoryBiopharmaceutical Stabilization Platform
Description

A patent-protected method for encasing thermally unstable biomolecules (vaccines, antibodies, enzymes, genetic material, probiotics) within a silica network, enabling storage and transport at temperatures from -80°C to +50°C without cold-chain logistics. Licensed to biopharmaceutical companies for integration into their manufacturing processes.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Spin Up Science Ventures
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-28
Description

Venture accelerator dedicated to supporting early stage academic breakthroughs. Part of Spin Up Science Ventures portfolio. Advised by Dr Ben Miles. Supported EnsiliTech's growth, regulatory, and commercial plans from spin-out through funding rounds.

ensilitech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-07
Description

Awarded £1.4M Innovate UK collaborative R&D grant to develop and implement Ensilication technology in monoclonal antibody production (based on Trastuzumab). CPI provides formulation expertise, scale-up support, economic analysis, and life cycle assessment. Represents key validation of technology integration into pharmaceutical manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

World-leading centre for research and surveillance of virus diseases of farm animals and viruses spreading from animals to humans (UK). Led the two-year £1.5M Nipah virus vaccine project. Professor Simon Graham leads the PRRS Group working on the bivalent NiV vaccine development.

4Friedrich-Loeffler-Institute (FLI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

Based in Germany. Partner in the Nipah virus vaccine consortium. Provides expertise in genetic engineering of pseudorabies virus for vaccine development. Dr Walter Fuchs stated the project aims to develop a vaccine providing immunity after a single shot.

ensilitech.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

UK company developing innovative rapid lateral flow immunoassay tests. Part of the Nipah virus vaccine consortium, developing a companion diagnostic test that discriminates infected from vaccinated animals (DIVA test).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-09
Description

Part of the Nipah virus vaccine consortium, providing expert insight into vaccine research and development alongside EnsiliTech's thermally stable vaccine technology.

7Afrigen Biologics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-23
Description

Based in Cape Town, South Africa. Partner in the SBRI-funded Hantaan virus mRNA vaccine project. Afrigen is the centre of WHO/MPP mRNA technology transfer programme developing and transferring mRNA technology to 15 manufacturing partners in LMICs. CEO Prof Petro Terblanche stated ensilication will eliminate or reduce cold-chain logistics.

ensilitech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-23
Description

Based in Houston, USA. Spin out from University of Texas Medical Branch and Galveston National Laboratory. Specialises in formulation of novel vaccines against neglected diseases. Partner in the SBRI-funded Hantaan virus mRNA vaccine project. CEO Dr Peter D. Weinstein will apply novel mRNA vaccine platform technology.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-01-23
Description

Regulatory affairs consultancy providing expert regulatory strategy support for the SBRI Hantaan virus vaccine project. Specialist in pharmaceutical, biotechnology, and medical device regulatory expertise across the full development process.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-23
Description

Nine-month programme at NYU Stern School of Business for massively scalable science and deep tech startups. EnsiliTech was accepted into EFL (nearly 1,400 applicants, only 78 accepted). Provides mentorship from serial entrepreneurs, investors, and technical mentors to accomplish individualized business goals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-27
Description

Spin-out origin. Dr Asel Sartbaeva developed ensilication over 12 years at the University of Bath. The company spun out from University of Bath in July 2022. HRH The Duke of Edinburgh visited the university in January 2025 and was shown EnsiliTech's technology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-07-27
Description

Dr Asel Sartbaeva is a Royal Academy of Engineering Enterprise Fellow through the Enterprise Hub. The company is also part of the Royal Academy of Engineering Shott Scale-up accelerator. The Academy provides fellowship, mentorship, and scale-up support.

13We Are Pioneers Group (LAUNCH programme)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-07-27
Description

Part of the LAUNCH programme with We Are Pioneers Group, supporting the development and commercialisation of deep tech ventures.

ensilitech.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a supporter on EnsiliTech's website. EnsiliTech featured as Royal Society of Chemistry Deep Tech Change Maker at ChemUK 2025, with a dedicated case study published by the RSC exploring the company's evolution from academic research to scalable deep tech innovation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a supporter. EnsiliTech participated in SETsquared Scale-up programme. The company won the Biggest Game-Changing Technology award from SETSquared in 2017.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish small-cap biotech developing air-drying technology (LumDry) to produce thermostable vaccines and biologics — a near-direct alternative-platform peer targeting the same cold-chain elimination pain point as Ensilication.

2Stabilitech Biopharma
TypeDirect peer
Description

UK/US biotech developing thermally stable oral and nasal vaccine formulations using proprietary stabilisation platforms — directly comparable technology category, customer base (vaccine developers), and pre-commercial stage.

TypeDirect peer
Description

US-based biotech developing a wax-in-water emulsion platform (Alhydrova) for thermostable vaccines; competes head-to-head with Ensilication for biopharma licensing deals in thermostable vaccine formulations.

TypeBroad incumbent
Description

Large specialty chemicals company with a significant biopharma excipients and adjuvants franchise, including vaccine stabilizers — a broad incumbent with overlapping capabilities in biologics stabilisation and the manufacturing relationships that EnsiliTech must reach via licensing.

TypeBroad incumbent
Description

Clinical-stage mRNA company developing self-amplifying and conventional mRNA therapeutics; a broader mRNA player whose thermostability investments are a competitive backdrop to EnsiliTech's thermally stable mRNA platform.

TypeEmerging player
Description

Clinical-stage company developing a high-density microarray patch (HD-MAP) for needle-free vaccine delivery with demonstrated thermal stability benefits — an adjacent enabling technology that could complement or compete with Ensilication in last-mile vaccine delivery.

TypeOthers
Description

UK technology innovation centre for biologics and pharmaceutical process development — currently an EnsiliTech co-development partner but also a broader ecosystem participant whose other bioprocess clients represent both potential collaborators and competitors.

8Afrigen Biologics
TypeOthers
Description

South African CDMO at the centre of the WHO/MPP mRNA technology transfer programme — an EnsiliTech collaborator on the Hantaan programme and an emerging hub for LMIC vaccine manufacturing that could either be a channel partner or build competing thermostable capabilities.

TypeBroad incumbent
Description

Global mRNA vaccine leader with deep R&D resources and ongoing work on next-generation thermostable mRNA formulations — a large strategic incumbent that could acquire competing platforms or build a comparable ensilication-style capability in-house.

TypeEmerging player
Description

Early-stage biotech developing nanoparticle-based preservation and delivery technologies for biologics — an emerging player with partial overlap in the biomolecule stabilisation space EnsiliTech targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EnsiliTech

Biopharmaceutical Stabilization Technologyensilitech.com

EnsiliTech is a Bristol-based biopharmaceutical spin-out from the University of Bath that licenses its patent-protected Ensilication® silica-encasement technology to pharma and biotech companies, enabling cold-chain-free storage of vaccines, antibodies, mRNA, and other biologics.

What EnsiliTech does

EnsiliTech (legal name: Ensilicated Technologies Ltd.) is a Bristol, UK-based biopharmaceutical company founded in July 2022 as a spin-out from the University of Bath, where co-founder and CEO Dr Asel Sartbaeva spent 12 years developing the underlying technology. The company commercializes Ensilication®, a patent-protected method of encasing thermally unstable biomolecules within an inert silica (glass) network that preserves their integrity across a temperature range of -80°C to +50°C, removing dependence on cold-chain refrigeration and lyophilization. Application areas span therapeutic and diagnostic antibodies, mRNA and other genetic material, subunit/viral/virus-like/bacterial vaccines, anti-microbial resistance products, probiotics, and enzymes for human, animal, and laboratory research use. EnsiliTech is developing lead programs including the world's first thermally stable mRNA vaccine against Hantaan Virus (funded by a ~£1.7M UK Government SBRI contract awarded January 2024) and a Nipah virus vaccine for livestock (two-year £1.5M DHSC/UK Vaccine Network project in consortium with Pirbright Institute, FLI, and partners), alongside a £1.4M Innovate UK–funded monoclonal antibody manufacturing project with CPI based on Trastuzumab.

The company's business model is a B2B technology licensing and co-development platform aimed at pharmaceutical and biotechnology manufacturers, with a stated pipeline of live commercial negotiations with billion-euro pharma partners. The GTM motion is sales-led enterprise licensing supported by co-development and validation partnerships with technology innovation centers (CPI), global health consortia (Afrigen, EmerVax, Pirbright, FLI, Global Access Diagnostics), and government health agencies (UK DHSC, Innovate UK, UK Vaccine Network). To date, ~£5.7M has been raised in equity (£1.2M pre-seed in January 2023 led by Science Angel Syndicate; £4.5M seed in August 2025 led by Eos Advisory) and an additional ~£4.6M in non-dilutive government grants. Revenue is currently grant-driven; commercial licensing royalties are not yet booked. The team comprises approximately 14–19 personnel — scientists, project managers, and executives — led by founder/CEO Dr Sartbaeva with commercial oversight from CCO Dr Simon Bennett (three decades of bio-pharma deals) and Chair Dr Tim Sparey (US$6B+ in life sciences transactions). The company is registered in England and Wales (company number 13537400) and holds granted patents, registered trademarks, and a growing IP portfolio, with the platform recognized through numerous awards including UK StartUp Awards 2025 (Overall StartUp of the Year South West) and the Allica Bank Great British Entrepreneur Awards 2025.

EnsiliTech firmographics

Firmographics
Name
EnsiliTech
Legal name
Ensilicated Technologies Ltd.
Website
https://ensilitech.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
EnsiliTech is a Bristol-based biopharmaceutical spin-out from the University of Bath that licenses its patent-protected Ensilication® silica-encasement technology to pharma and biotech companies, enabling cold-chain-free storage of vaccines, antibodies, mRNA, and other biologics.
Ownership category
akta.pro rank

EnsiliTech industry classification

Industry
Product category
Biopharmaceutical Stabilization Technology
NAICS
Air-Conditioning and Warm Air Heating Equipment and Commercial and Industrial Refrigeration Equipment Manufacturing (333415)
SIC
Gaskets, Packg & Sealg Devices & Rubber & Plastics Hose (3050)
akta.pro industry
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAC
Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAMAF
Packaging, Insulation & Temperature-Controlled Shippers (Qualified Systems)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Biopharmaceutical stabilization technology
  • Cold-chain-free vaccines
  • Vaccine thermostabilization platform
  • Biomolecule silica encapsulation
  • Biologics preservation technology

Where EnsiliTech is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

EnsiliTech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Technology Licensing: Plans to license Ensilication technology to biopharma companies to create heat-stable versions of their medicines. The company is in live commercial negotiations with billion-euro pharma partners for technology integration.
  2. Government R&D Contracts: Awarded UK Government SBRI research contracts (~£1.7M for Hantaan virus vaccine). Innovate UK grant funding for collaborative R&D projects. These represent non-dilutive funding for technology development and validation.
  3. Collaborative R&D / Service Fees: Collaborative development agreements with pharmaceutical partners such as CPI for antibody manufacturing, and consortium projects with Pirbright, Afrigen, and EmerVax. Revenue may come from development fees, milestone payments, and validation study contracts.

Go-to-market motion1 record

Distribution channels3 records

EnsiliTech product offering

Product offering

Core offering

EnsiliTech develops and licenses Ensilication®, a patent-protected platform technology that encases thermally unstable biomolecules (vaccines, antibodies, enzymes, mRNA, probiotics) within a silica network to prevent degradation at temperatures from -80°C to +50°C, eliminating the need for cold-chain refrigeration. The company licenses this stabilization technology to biopharma manufacturers and conducts collaborative R&D projects with research institutes and government agencies.

Product overview

EnsiliTech offers the Ensilication® platform technology as its core product—a novel, patent-protected method for stabilizing biopharmaceuticals without refrigeration. The platform encases thermally unstable biomolecules (vaccines, antibodies, enzymes, genetic material, probiotics) within a silica network, allowing storage and transport at temperatures from -80°C to +50°C. The company licenses this technology to biopharma companies and is applying it through several programs including development of a thermally stable mRNA vaccine against Hantaan Virus (via SBRI contract) and antibody stabilization (via CPI partnership grant). EnsiliTech also publishes white papers and research to demonstrate the technology's application and economics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ensilication® Platform Technology A patent-protected method for encasing thermally unstable biomolecules (vaccines, antibodies, enzymes, genetic material, probiotics) within a silica network, enabling storage and transport at temperatures from -80°C to +50°C without cold-chain logistics. Licensed to biopharmaceutical companies for integration into their manufacturing processes.

Companies that use EnsiliTech

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

EnsiliTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EnsiliTech partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Spin Up Science VenturescoreStrategic or Co-development Partner · 28 August 2025Venture accelerator dedicated to supporting early stage academic breakthroughs. Part of Spin Up Science Ventures portfolio. Advised by Dr Ben Miles. Supported EnsiliTech's growth, regulatory, and commercial plans from spin-out through funding rounds.
  • CPI (Centre for Process Innovation)coreStrategic or Co-development Partner · 7 March 2025Awarded £1.4M Innovate UK collaborative R&D grant to develop and implement Ensilication technology in monoclonal antibody production (based on Trastuzumab). CPI provides formulation expertise, scale-up support, economic analysis, and life cycle assessment. Represents key validation of technology integration into pharmaceutical manufacturing.
  • The Pirbright InstitutecoreStrategic or Co-development Partner · 9 May 2024World-leading centre for research and surveillance of virus diseases of farm animals and viruses spreading from animals to humans (UK). Led the two-year £1.5M Nipah virus vaccine project. Professor Simon Graham leads the PRRS Group working on the bivalent NiV vaccine development.
  • Friedrich-Loeffler-Institute (FLI)coreStrategic or Co-development Partner · 9 May 2024Based in Germany. Partner in the Nipah virus vaccine consortium. Provides expertise in genetic engineering of pseudorabies virus for vaccine development. Dr Walter Fuchs stated the project aims to develop a vaccine providing immunity after a single shot.
  • Global Access DiagnosticsminorStrategic or Co-development Partner · 9 May 2024UK company developing innovative rapid lateral flow immunoassay tests. Part of the Nipah virus vaccine consortium, developing a companion diagnostic test that discriminates infected from vaccinated animals (DIVA test).
  • BioVacc ConsultingminorStrategic or Co-development Partner · 9 May 2024Part of the Nipah virus vaccine consortium, providing expert insight into vaccine research and development alongside EnsiliTech's thermally stable vaccine technology.
  • Afrigen BiologicscoreStrategic or Co-development Partner · 23 January 2024Based in Cape Town, South Africa. Partner in the SBRI-funded Hantaan virus mRNA vaccine project. Afrigen is the centre of WHO/MPP mRNA technology transfer programme developing and transferring mRNA technology to 15 manufacturing partners in LMICs. CEO Prof Petro Terblanche stated ensilication will eliminate or reduce cold-chain logistics.
  • EmerVaxcoreStrategic or Co-development Partner · 23 January 2024Based in Houston, USA. Spin out from University of Texas Medical Branch and Galveston National Laboratory. Specialises in formulation of novel vaccines against neglected diseases. Partner in the SBRI-funded Hantaan virus mRNA vaccine project. CEO Dr Peter D. Weinstein will apply novel mRNA vaccine platform technology.
  • S-cubed LtdminorImplementation/ SI/ Consulting Partner · 23 January 2024Regulatory affairs consultancy providing expert regulatory strategy support for the SBRI Hantaan virus vaccine project. Specialist in pharmaceutical, biotechnology, and medical device regulatory expertise across the full development process.
  • Endless Frontier Labs (EFL)minorStrategic or Co-development Partner · 23 October 2023Nine-month programme at NYU Stern School of Business for massively scalable science and deep tech startups. EnsiliTech was accepted into EFL (nearly 1,400 applicants, only 78 accepted). Provides mentorship from serial entrepreneurs, investors, and technical mentors to accomplish individualized business goals.
  • University of BathcoreStrategic or Co-development Partner · 27 July 2022Spin-out origin. Dr Asel Sartbaeva developed ensilication over 12 years at the University of Bath. The company spun out from University of Bath in July 2022. HRH The Duke of Edinburgh visited the university in January 2025 and was shown EnsiliTech's technology.
  • Royal Academy of Engineering Enterprise HubminorStrategic or Co-development Partner · 27 July 2022Dr Asel Sartbaeva is a Royal Academy of Engineering Enterprise Fellow through the Enterprise Hub. The company is also part of the Royal Academy of Engineering Shott Scale-up accelerator. The Academy provides fellowship, mentorship, and scale-up support.
  • We Are Pioneers Group (LAUNCH programme)minorStrategic or Co-development Partner · 27 July 2022Part of the LAUNCH programme with We Are Pioneers Group, supporting the development and commercialisation of deep tech ventures.
  • Royal Society of ChemistryminorStrategic or Co-development PartnerListed as a supporter on EnsiliTech's website. EnsiliTech featured as Royal Society of Chemistry Deep Tech Change Maker at ChemUK 2025, with a dedicated case study published by the RSC exploring the company's evolution from academic research to scalable deep tech innovation.
  • SETSquaredminorStrategic or Co-development PartnerListed as a supporter. EnsiliTech participated in SETsquared Scale-up programme. The company won the Biggest Game-Changing Technology award from SETSquared in 2017.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

EnsiliTech competitors and assessment

Company assessment

Direct peers

  • Ziccum AB: Swedish small-cap biotech developing air-drying technology (LumDry) to produce thermostable vaccines and biologics — a near-direct alternative-platform peer targeting the same cold-chain elimination pain point as Ensilication.
  • Stabilitech Biopharma: UK/US biotech developing thermally stable oral and nasal vaccine formulations using proprietary stabilisation platforms — directly comparable technology category, customer base (vaccine developers), and pre-commercial stage.
  • VitriVax: US-based biotech developing a wax-in-water emulsion platform (Alhydrova) for thermostable vaccines; competes head-to-head with Ensilication for biopharma licensing deals in thermostable vaccine formulations.

Broad incumbents

  • Croda International: Large specialty chemicals company with a significant biopharma excipients and adjuvants franchise, including vaccine stabilizers — a broad incumbent with overlapping capabilities in biologics stabilisation and the manufacturing relationships that EnsiliTech must reach via licensing.
  • Arcturus Therapeutics: Clinical-stage mRNA company developing self-amplifying and conventional mRNA therapeutics; a broader mRNA player whose thermostability investments are a competitive backdrop to EnsiliTech's thermally stable mRNA platform.
  • BioNTech: Global mRNA vaccine leader with deep R&D resources and ongoing work on next-generation thermostable mRNA formulations — a large strategic incumbent that could acquire competing platforms or build a comparable ensilication-style capability in-house.

Emerging players

  • Vaxxas: Clinical-stage company developing a high-density microarray patch (HD-MAP) for needle-free vaccine delivery with demonstrated thermal stability benefits — an adjacent enabling technology that could complement or compete with Ensilication in last-mile vaccine delivery.
  • Xerion Healthcare: Early-stage biotech developing nanoparticle-based preservation and delivery technologies for biologics — an emerging player with partial overlap in the biomolecule stabilisation space EnsiliTech targets.

Others

  • CPI (Centre for Process Innovation): UK technology innovation centre for biologics and pharmaceutical process development — currently an EnsiliTech co-development partner but also a broader ecosystem participant whose other bioprocess clients represent both potential collaborators and competitors.
  • Afrigen Biologics: South African CDMO at the centre of the WHO/MPP mRNA technology transfer programme — an EnsiliTech collaborator on the Hantaan programme and an emerging hub for LMIC vaccine manufacturing that could either be a channel partner or build competing thermostable capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EnsiliTech social profiles

Digital presence

EnsiliTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EnsiliTech leadership team

Management profile

Number of profiles

Profiles12 records

EnsiliTech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EnsiliTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnsiliTech

What does EnsiliTech do?

EnsiliTech develops and licenses Ensilication®, a patent-protected platform technology that encases thermally unstable biomolecules (vaccines, antibodies, enzymes, mRNA, probiotics) within a silica network to prevent degradation at temperatures from -80°C to +50°C, eliminating the need for cold-chain refrigeration. The company licenses this stabilization technology to biopharma manufacturers and conducts collaborative R&D projects with research institutes and government agencies.

Is EnsiliTech a public or private company?

EnsiliTech is a private company. It is classified as venture growth investor backed and is currently operating.

When was EnsiliTech founded?

EnsiliTech was founded in 2022. It employs 11 to 50 people.

Where is EnsiliTech based?

EnsiliTech is headquartered in Bristol, United Kingdom, in the Europe region.

How does EnsiliTech make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are government R&D Contracts and collaborative R&D / Service Fees.

Who are EnsiliTech's main competitors?

Direct peers on record are Ziccum AB, Stabilitech Biopharma and VitriVax. Broad incumbents are Croda International, Arcturus Therapeutics and BioNTech. Emerging players are Vaxxas and Xerion Healthcare. Others are CPI (Centre for Process Innovation) and Afrigen Biologics.

Does EnsiliTech have an API?

No public API is recorded for EnsiliTech.

What industry is EnsiliTech in?

EnsiliTech's product category is Biopharmaceutical Stabilization Technology. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAAAJAC, Single-Use Technologies (SUT) & Disposable Fluid Management (bags, assemblies, connectors). Its NAICS code is 333415 and its SIC code is 3050.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business LiveBristol lab developing hantavirus vaccine 'excited' after breakthroughEnsilitech, a Bristol-based spin-out, reported a breakthrough in developing a vaccine for hantaan hantavirus, which has been tested in labs and works on animals. The company seeks continued funding to advance to pre-clinical development and human trials, with a potential vaccine ready in three to four years.VentureRadarNew Funding Rounds in Cold chainThe article lists multiple recent funding rounds for companies in the cold chain and logistics sectors, including Neolix Technologies raising over US $600 million and Zelos Technology securing $100 million. Other featured transactions include Ripplr's INR 200 crore raise, EnsiliTech's £4.5 million funding, and Vaxxas's $49 million Series D. The content aggregates these venture capital events without focusing on a single narrative.TechRoundStartup Of The Week: EnsiliTechEnsiliTech is a Bristol-based biotech startup founded in 2022 by Dr. Asel Sartbaeva that has developed a patented technology called Ensilication, which wraps medicines and vaccines in a silica shell to keep them stable without refrigeration. The technology addresses the cold chain problem that costs the pharmaceutical industry an estimated £26 billion annually and results in up to half of all vaccines being wasted due to temperature failures. The company has completed a £4.5 million seed round and received Innovate UK grant funding, and plans to license its technology to biopharma companies to create heat-stable versions of their medicines.FinSMEsEnsiliTech Raises £4.5M in Seed FundingEnsiliTech, a Bristol-based biotechnology startup, raised £4.5M in seed funding led by Eos Advisory and Calculus Capital. The company will use the funds to accelerate growth and enhance its infrastructure capabilities. It aims to make biopharmaceuticals room-temperature stable to improve access and reduce environmental impact.Tech.euEnsiliTech raises £4.5M to advance medicine formulationEnsiliTech raised £4.5M in seed funding to advance its Ensilication technology, which stabilizes biopharmaceuticals at room temperature. The company aims to reduce cold-chain costs and vaccine losses, with partners including Eos Advisory and Calculus Capital. The funding will support proof-of-concept adoption and validation studies.EnsilitechEnsiliTech® raises £4.5M to enhance medicine formulation and reduce global biopharmaceutical supply-chain emissions — EnsiliTechEnsiliTech raised £4.5M in seed funding led by Eos Advisory to improve biopharmaceutical storage and transport. Its Ensilication technology eliminates cold-chain refrigeration, reducing supply-chain costs and waste. The company plans to accelerate proof-of-concept uptake and generate validation data for pharmaceutical manufacturing.BebeezBritish BioTech startup EnsiliTech raises €5.2 million to cut cold-chain costs in biopharma transport – BeBeez InternationalEnsiliTech, a Bristol-based biotech startup, raised €5.2 million in seed funding led by Eos Advisory to develop a thermostabilization technology for biopharmaceuticals. The company's Ensilication technology stabilizes medicines at up to 50°C, aiming to cut cold-chain costs and reduce vaccine waste. The funding will support team expansion and validation studies.UKTNBristol’s EnsiliTech raises £4.5m for vaccine transport systemBristol-based biotech startup EnsiliTech has secured a £4.5m seed investment to scale its patented technology for transporting and storing vaccines, antibodies, and enzymes without refrigeration. The company's technology can preserve vaccine integrity at temperatures up to 50°C, addressing the biopharmaceutical industry's reliance on costly cold-chain systems and enabling distribution to regions without reliable refrigeration infrastructure. The funding round was led by Eos Advisory with participation from Calculus Capital, Empirical Ventures, and several other investors, following a previous £1.2m round in 2023.EnsilitechEnsiliTech® and CPI Awarded Sustainable Medicines Manufacturing Grant to Revolutionise Antibody Manufacturing with Cold-Chain Free Technology — EnsiliTechEnsiliTech and CPI received a £1.4M Innovate UK grant to develop Ensilication technology that stabilizes antibodies at room temperature, eliminating cold-chain dependence. The project will test the technology with Trastuzumab and conduct cost-of-goods analysis. The collaboration aims to improve accessibility and reduce manufacturing costs for antibody therapies.BusinessCloudBath spinout wins government contract for life-saving vaccine techA University of Bath spinout, EnsiliTech, won a £1.7 million UK government contract to develop a thermally stable mRNA vaccine. The two-year project aims to create a vaccine platform that does not require refrigeration, with a second five-year contract expected. The technology could revolutionize vaccine distribution, especially in remote areas.